Hypertrophic cardiomyopathy in children.

Area of Science:

• Cardiology
• Genetics
• Pediatrics

Background:

• Hypertrophic cardiomyopathy (HCM) is a congenital heart disease with diverse genetic and phenotypic expressions.
• Manifestations can occur across all age groups, from infancy to young adulthood.
• Requires personalized medical management due to its heterogeneity.

Purpose of the Study:

• To highlight the individualized approach needed for managing hypertrophic cardiomyopathy.
• To emphasize the importance of early identification and treatment strategies.
• To discuss the role of genotyping in predicting disease course and preventing sudden death.

Main Methods:

• Review of clinical presentations and management strategies for hypertrophic cardiomyopathy.
• Discussion of genotypic and phenotypic heterogeneity.
• Emphasis on risk stratification for sudden cardiac death.

Main Results:

• Symptomatic patients may experience disease progression but can benefit from medical or surgical therapies.
• Symptomatic infants often have a poor prognosis, necessitating early heart transplant consideration.
• Genotyping holds promise for identifying high-risk individuals for aggressive treatment to prevent sudden death.

Conclusions:

• Individualized medical management is essential for hypertrophic cardiomyopathy.
• Early recognition of at-risk asymptomatic patients, particularly by primary care physicians, is critical for preventing sudden death during athletic activities.
• Future advancements in genotyping may improve prognostication and therapeutic strategies.